AAD 2024 LATEBREAKER: Delgocitinib for Long-Term Use in Chronic Hand Eczema

05/27/24 • 19 min

🎙️ Melinda Knows Best at the AAD! 🌟

We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego!

👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!

We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema.

Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Practical Tips for Dermatology Practices 🏥💼

Adapting treatment plans for chronic hand eczema.
Benefits of as-needed treatment approaches for better patient outcomes.

Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️

Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫

Episode Learning Objectives:

Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments

Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫

🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍

Episode supported by an IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Dermatologist | Toronto

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

References

Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

📻www.skinandjoints.ca

✉️[email protected]

🎙️ Melinda Knows Best at the AAD! 🌟

We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego!

👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!

We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema.

Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Practical Tips for Dermatology Practices 🏥💼

Adapting treatment plans for chronic hand eczema.
Benefits of as-needed treatment approaches for better patient outcomes.

Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️

Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫

Episode Learning Objectives:

Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments

Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫

🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍

Episode supported by an IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Dermatologist | Toronto

Toronto, ON

References

Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

📻www.skinandjoints.ca

✉️[email protected]

Previous Episode

AAD 2024 Mini Podcast: Alopecia Areata with Dr.Diana Diao

🎙️🌞 Tight Spaces & Hair-Raising Breakthroughs – Live from AAD San Diego! 🎙️🌴

Join Skin and Joints Podcast AAD Guest Faculty and Vancouver based dermatologist, Dr,Diana Diao, as she navigates the cramped quarters of a historic boutique hotel in the Gaslamp Quarter—tiny rooms, weird noises, and all! 🏨😅

Dr. Diao explore groundbreaking sessions on alopecia areata, revealing innovative treatments and valuable clinical insights that are shaping the future of dermatology.

🌟💊Don't miss out on Dr. Diao's top clinical takeaways that could revolutionize treatment approaches for dermatologists everywhere. Whether it's systemic therapies for extensive scalp involvement or tailored treatments for unique patient profiles, this episode is packed with insights that promise to enhance patient care.

💬 Tune in, transform your approach with pearls that could change your practice overnight!

🎧✨ #SkinJointsPodcast #DermatologyInDepth

Learning Objectives:

Gain Insight into New Treatments for Alopecia Areata: Learn about the latest advancements and clinical trials discussed at AAD, including newly approved treatments and their application in real world practice.
Appreciate the Psychosocial Aspects of Dermatological Conditions: Recognize the significant emotional and social challenges faced by patients with alopecia areata and the importance of addressing these in real world practice.
Implement Clinical Pearls in Practice: Discover actionable tips and strategies that can be immediately applied to improve patient outcomes.

#SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun
Episode supported by an IME Grant from Pfizer and Bausch Health.

ABOUT DR. DIANA DIAO FRCPC, FAAD

Dermatologist | Vancouver, BC

Dr. Diana Diao is a Dermatologist and a Clinical Instructor in the Department of Dermatology and Skin Science at the University of British Columbia. She is a consultant dermatologist at both Vancouver General Hospital and St. Paul’s Hospital. Dr. Diao practices medical and procedural dermatology, with a special interest in using energy-based modalities such as lasers to treat a variety of skin conditions.

Dr. Diao completed both her Medical Doctorate degree and dermatology residency training at the University of British Columbia, and is a Fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Diao is a mother, a published author, and has presented her work at conferences such as the World Congress of Dermatology and the American Academy of Dermatology meetings. Dr. Diao is also fluent in Mandarin.

📻www.skinandjoints.ca

✉️[email protected]

Next Episode

PART 1: My CaSMO Playbook Managing Skin Toxicities in Oncology Treatment with Dr.Maxwell Sauder

🌞🎧Dermatologist Dr.Max Sauder joins us and navigates us through the complexities of modern dermatological care💡

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 1🎙️

Get ready for a laugh and learn session as Dr. Jessica Asgarpour takes the co-hosting hot seat! This episode, we’re diving headfirst into the CASMO project with dermo-oncologist Dr. Max Sauder. We’ll decode the CASMO algorithm, tackle the nitty-gritty of managing skin toxicities, and even uncover Dr. Sauder's secret summer plans. Buckle up! 🎢

We're peeling back the layers of the CASMO project, an innovative approach to managing skin toxicities in cancer treatment. Can certain skin toxicities be prevented in patients? Is there a proactive skincare regimen that can be recommended?

Introduction to CaSMO and Skin Toxicities in Cancer Treatment: Overview of the significance of managing skin toxicities, introducing the CaSMO algorithm's development and objectives.
Prevention Strategies: Detailed discussion on general skincare measures recommended by CaSMO, including the rationale behind the use of cleansers and moisturizers to maintain skin hydration and integrity.

Episode Learning Objectives:

Understand the CASMO algorithm and its role in managing skin toxicities associated with cancer treatments.
Recognize the importance of a multidisciplinary approach in improving patient outcomes.
Identify practical proactive strategies for preventing and managing skin toxicities.
Learn about the impact of skin toxicities on patients' quality of life and how to address these issues.
Explore the role of various healthcare providers, including oncologists, nurses, and pharmacists, in supporting patients through their cancer journey.

Press play for a dose of dermatological delight 🎙️✨

Episode supported by an IME Grant from LA ROCHE POSAY

REFERENCES AND FURTHER RESOURCES:

1. The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2. Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3. Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4. Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5. Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6. Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption,...